|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD966.15
million
|
|
CAGR
(2023-2028)
|
13.54%
|
|
Fastest
Growing Segment
|
Custom
Nucleic Acid
|
|
Largest
Market
|
China
|
Market Overview
Asia Pacific Nucleic Acid Therapeutics CDMO Market
has valued at USD966.15 million in 2022 and is anticipated to project robust
growth in the forecast period with a CAGR of 13.54% through 2028. This surge in
the Asia Pacific Nucleic Acid Therapeutics CDMO market is primarily driven by
increased research and development activities, including extensive exploration
of novel therapeutic approaches, advancements in biotechnology, and strong
governmental support and funding. The region has witnessed a remarkable rise in
research and development endeavors, particularly in the field of nucleic acid
therapeutics, which has garnered significant attention from countries like
China, Japan, India, and South Korea. These nations are heavily investing in
innovative treatment approaches that target the root cause of diseases at the
genetic level, aiming to revolutionize medical practices.
One of the key factors contributing to the market
growth is the growing number of clinical trials and the expanding pipeline of
nucleic acid therapeutics in the Asia Pacific region. The region has witnessed
a surge in the clinical number of clinical trials, highlighting the increasing
focus on developing effective therapies. This rise in research activities,
coupled with the introduction of cutting-edge therapies, has significantly
propelled the market growth in the region.
Technological advancements in biotechnology have
played a pivotal role in transforming the field of nucleic acid therapeutics.
The emergence of gene editing tools such as CRISPR-Cas9 and next-generation
sequencing technologies has revolutionized the way genetic disorders and
cancers are treated. These remarkable advancements have enabled precise and
controlled manipulation of genetic material, paving the way for breakthrough
treatments. Consequently, the Asia Pacific region has experienced a surge in
research and development activities, further driving the demand for Contract
Development and Manufacturing Organizations (CDMOs).
Despite the promising growth prospects, the Asia
Pacific Nucleic Acid Therapeutics CDMO market faces certain challenges. High
production costs, complex manufacturing processes, and stringent regulatory
environments pose hurdles to the market's expansion. However, these challenges
are gradually being addressed through continuous technological advancements and
the establishment of more conducive regulatory frameworks, fostering an
environment for sustained growth and innovation in the region.
Key Market Drivers
Growing Prevalence of Chronic Diseases
The Asia Pacific region is currently facing a
significant and escalating burden of chronic diseases, such as cancer,
cardiovascular diseases, diabetes, and respiratory conditions. According to the
World Health Organization, non-communicable diseases (NCDs) account for a staggering
71% of all deaths globally, with nearly half of these NCD deaths occurring in
the Asia Pacific region. This alarming rise in chronic diseases has heightened
the demand for advanced therapeutic solutions, thereby propelling the growth of
the nucleic acid therapeutics industry.
Nucleic acid therapeutics offer a promising avenue
for the treatment of various chronic diseases. These innovative therapies
operate at the genetic level, targeting the very root cause of the disease
rather than merely alleviating symptoms. This approach holds immense potential
for providing curative solutions for numerous conditions, including genetic
disorders and cancers, which have traditionally posed significant challenges
for conventional therapeutics.
As the demand for these groundbreaking treatments
continues to surge, the need for Contract Development and Manufacturing
Organizations (CDMOs) specializing in nucleic acid therapeutics becomes
increasingly paramount. CDMOs offer a comprehensive range of services, spanning
from initial drug development to large-scale commercial manufacturing, thereby
enabling drug companies to expedite the launch of their products and reach
patients in a timelier manner.
The rise in chronic diseases has resulted in an
exponential increase in the number of nucleic acid-based drugs in the pipeline.
Consequently, there is a growing imperative for robust manufacturing
capabilities to support the scale-up and commercialization of these
transformative therapies. This is precisely where CDMOs play a critical role,
providing the necessary expertise and infrastructure to manufacture these
highly complex therapies. As a result, the nucleic acid therapeutics CDMO
market in the Asia Pacific region is experiencing remarkable growth and
expansion.
Expansion in Biopharmaceutical Industry
Asia Pacific, home to some of the fastest-growing
economies in the world, has witnessed a remarkable expansion in its
biopharmaceutical industry in recent years. Countries like China, India, South
Korea, and Singapore have emerged as global hubs for biopharmaceutical research
and development (R&D), attracting significant domestic and international
investments.
This expansion in the biopharmaceutical industry
can be attributed to a combination of factors. Firstly, there has been a surge
in the demand for advanced therapeutics, driven by a growing need for
innovative treatment options for various diseases. Additionally, the rising
middle class in the region, with increased affordability and access to
healthcare, has further fueled the demand for such treatments.
Government initiatives have played a crucial role
in fostering the growth of the biopharmaceutical sector in the Asia Pacific
region. These initiatives include policies and funding support that encourage
biopharmaceutical R&D, promoting collaborations between academia, industry,
and research institutes to drive innovation and accelerate the development of
novel therapies.
Nucleic acid therapeutics, encompassing DNA and
RNA-based therapies, have emerged as frontrunners in the biopharmaceutical
revolution. By targeting the genetic basis of diseases, these therapies offer
groundbreaking treatment options for a wide range of conditions, including
genetic disorders, cancers, and viral infections. The potential of nucleic acid
therapeutics has garnered significant interest and investment, leading to a
surge in the number of such drugs in the pipeline.
As the interest in nucleic acid therapeutics
continues to grow, there is an increasing need for specialized Contract
Development and Manufacturing Organizations (CDMOs) that can support their
development and manufacturing. These specialized CDMOs offer a range of
services such as plasmid DNA production, viral vector manufacturing, and mRNA
synthesis, enabling efficient and scalable production of nucleic acid
therapeutics.
With the expanding biopharmaceutical industry in
the Asia Pacific region, the demand for these specialized CDMO services has
witnessed a significant surge. This heightened demand has, in turn, fueled the
growth of the nucleic acid therapeutics CDMO market in the region, establishing
Asia Pacific as a key player in the global biopharmaceutical landscape.
Download Free Sample Report
Key Market Challenges
Disruptions in Supply Chain
Supply chain disruptions can have far-reaching
consequences for any industry, including the biopharmaceutical sector. These
disruptions not only create delays in drug development and manufacturing
processes but also impact the timely delivery of life-saving therapies to
patients in need. The COVID-19 pandemic has further exacerbated these
challenges globally, forcing contract development and manufacturing
organizations to navigate complex obstacles.
In the Asia Pacific region, supply chain
restructuring continues to pose significant challenges for trade and customs
professionals. Even before the pandemic, global trade disputes and geopolitical
tensions were already causing disruptions. With the added pressure from
COVID-19, these challenges have intensified and have had a profound impact on
various sectors, including the nucleic acid therapeutics CDMO market.
Multiple factors contribute to the supply chain
disruptions in the Asia Pacific Nucleic Acid Therapeutics CDMO market. These
factors include transport and travel restrictions, geopolitical tensions, and
shifts in regulatory environments. Moreover, the complex nature of nucleic acid
therapeutics, which require specialized materials and strict storage and
transport conditions, further adds to the vulnerability of the supply chain,
making it crucial to address these challenges effectively.
Key Market Trends
Increased Outsourcing of Nucleic Acid Manufacturing
Over the past decade, the biopharmaceutical
industry has experienced a significant and noteworthy trend towards
outsourcing. This shift has been primarily driven by the ever-increasing
complexity of drug development and manufacturing processes, coupled with the
pressing need to optimize costs and improve overall efficiency.
In the realm of nucleic acid therapeutics, this
trend towards outsourcing becomes even more pronounced. The intricate and
intricate nature of nucleic acid manufacturing requires highly specialized
skills and dedicated facilities, making it quite challenging for many
pharmaceutical companies to carry out in-house production. As a result, these
companies are increasingly relying on Contract Development and Manufacturing
Organizations (CDMOs) that specialize specifically in the field of nucleic acid
therapeutics.
The increased outsourcing of nucleic acid
manufacturing processes has consequently fueled the growth and expansion of the
nucleic acid therapeutics CDMO market, particularly in the Asia Pacific region.
With pharmaceutical companies outsourcing a larger portion of their production
tasks, the demand for CDMO services has skyrocketed. This notable trend has led
to a surge in investments aimed at expanding CDMO capacities, thereby fostering
the growth and development of the CDMO market.
Moreover, the Asia Pacific region, renowned for its
cost-competitive environment and highly skilled workforce, is emerging as an
increasingly attractive destination for outsourcing nucleic acid therapeutics
manufacturing. Countries such as China, India, and South Korea are rapidly
evolving into global hubs for nucleic acid therapeutics manufacturing, further
propelling the growth and expansion of the CDMO market within this region.
The trend towards increased outsourcing of nucleic
acid manufacturing is expected to persist and continue well into the foreseeable
future. As more and more nucleic acid-based drugs enter the development
pipeline, coupled with the rising demand for these innovative therapies, the
need for specialized CDMOs will undoubtedly continue to grow. This trend
presents a promising and exciting opportunity for CDMOs operating within the
Asia Pacific region to further expand their services and effectively cater to
the ever-increasing demand for nucleic acid therapeutics.
Segmental Insights
Product Type Insights
Based on the category of product type, the custom nucleic
acid segment emerged as the dominant player in the Asia Pacific market for nucleic
acid therapeutics CDMO in 2022. One of the primary reasons for the dominance of
custom nucleic acids is the growing demand for personalized therapies. In the
field of nucleic acid therapeutics, which encompasses innovative treatments
such as gene therapy and RNA interference, the potential for highly
individualized and targeted treatments is unprecedented. The ability to
precisely customize nucleic acids to specifically target and manipulate genetic
sequences holds the promise of more effective and tailored therapies,
revolutionizing the landscape of medicine.
Recent advancements in biotechnology have further
propelled the manufacturing of custom nucleic acids on a large scale. These
breakthroughs have not only increased the accuracy and efficiency of custom
nucleic acid synthesis but have also rendered them a viable and practical
option for drug development and manufacturing. With the ability to provide
tailored treatments and the potential to address a wide range of diseases and
conditions, custom nucleic acids are poised to play a pivotal role in the
future of precision medicine.
Technology Insights
The column-based method segment is projected to
experience rapid growth during the forecast period. The column-based method is
widely recognized and valued for its exceptional efficiency and unparalleled
reliability in the purification of nucleic acids. By utilizing advanced column
chromatography techniques, this method ensures the extraction of high-quality
and pure yield of nucleic acids, which holds immense significance in the
development and production of nucleic acid therapeutics. Given the stringent
quality requirements and regulatory standards in therapeutic manufacturing,
it's no surprise that this method remains the preferred choice among
researchers and industry professionals alike.
Another noteworthy factor that contributes to the
dominant position of the column-based method is its exceptional scalability.
This method can effortlessly be scaled up or down, depending on the desired
quantity of nucleic acids, making it an incredibly versatile and adaptable
choice for both small-scale research projects and large-scale production
facilities. This unique scalability not only enhances its practicality but also
streamlines the entire purification process, minimizing potential bottlenecks
and ensuring a seamless workflow.
Furthermore, one cannot overlook the significant
cost-effectiveness of the column-based method, which plays a pivotal role in
the realm processing time of time, this method drug development and
manufacturing. By eliminating the need for multiple purification steps and
reducing the overall processing time, this method not only saves valuable
resources but also optimizes operational efficiency. In an industry where
financial constraints are a constant consideration, the cost-effectiveness of
the column-based method proves to be a substantial advantage, further
solidifying its position as the preferred choice for nucleic acid purification.
Download Free Sample Report
Regional Insights
China emerged as the dominant player in the Asia
Pacific Nucleic Acid Therapeutics CDMO Market in 2022, holding the largest Market
share in terms of value. China's pharmaceutical industry has experienced
remarkable growth in recent years, fueled by a combination of factors. The
country's concerted efforts to modernize its healthcare system, coupled with
favorable government policies and increased research and development
investments, have created an environment ripe for the advancement of nucleic
acid therapeutics. The development of these cutting-edge treatments holds
immense potential for addressing complex diseases and improving patient
outcomes.
China's commitment to research and development in
the healthcare sector has yielded significant advancements. The country's
strategic investments have not only propelled innovation but have also paved
the way for the emergence of novel therapies, particularly in the realm of
nucleic acid-based treatments. These innovative approaches harness the power of
genetic material to target and treat diseases at their core, offering new
avenues for precision medicine and personalized healthcare.
Recent Developments
- In June 2021, Danaher Corporation, a global science
and technology innovator, successfully completed the acquisition of Aldeveron,
a leading biotechnology company, for a staggering USD 9.6 billion. This
strategic move positions Danaher Corporation at the forefront of the rapidly
expanding field of genetic medicine, as it significantly enhances their
manufacturing capacity in plasmid DNA and mRNA, the key building blocks of
cutting-edge therapeutics.
- Fast forward to January 2023, Agilent Technologies,
Inc., a renowned provider of life sciences, diagnostics, and applied chemical
solutions, made a substantial investment of USD 725 million to bolster their
manufacturing capacity for therapeutic nucleic acids. This strategic initiative
reinforces Agilent Technologies' commitment to advancing the frontier of
precision medicine, as they gear up to meet the growing demand for innovative
genetic therapies.
Key Market Players
- Asymchem Inc.
- BioCina
Pty Ltd.
- CMIC
HOLDINGS Co., Ltd.
- Kaneka
Corporation
- Nippon
Shkubai Co., Ltd
- Nitto
Inc.
- ST Pharm
Co Ltd
|
|
By
Technology
|
By Country
|
- Standard
Nucleic Acid
- Micro-Scale
Nucleic Acid
- Large-Scale
Nucleic Acid
- Custom
Nucleic Acid
- Modified
Nucleic Acid
- Primers
- Probes
- Others
|
- Column-Based
Method
- Microarray-Based
Method
|
- China
- Japan
- South Korea
- Australia
- India
- Rest of
Asia-Pacific
|
Report Scope:
In this report, the Asia Pacific Nucleic Acid
Therapeutics CDMO Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Asia Pacific Nucleic Acid Therapeutics CDMO
Market, By Product Type:
o Standard Nucleic Acid
o Micro-Scale Nucleic Acid
o Large-Scale Nucleic Acid
o Custom Nucleic Acid
o Modified Nucleic Acid
o Primers
o Probes
o Others
- Asia Pacific Nucleic Acid Therapeutics CDMO
Market, By Technology:
o Column-Based Method
o Microarray-Based Method
- Asia Pacific Nucleic Acid Therapeutics CDMO
Market, By Country:
o China
o Japan
o South Korea
o Australia
o India
o Rest of Asia-Pacific
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Asia
Pacific Nucleic Acid Therapeutics CDMO Market.
Available Customizations:
Asia Pacific Nucleic Acid Therapeutics CDMO Market
report with the given Market data, Tech Sci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and profiling of additional Market
players (up to five).
Asia Pacific Nucleic
Acid Therapeutics CDMO Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]